Fully underwritten rights issue of NOK 70 million - link to prospectus and online subscription

The extraordinary general meeting in PCI Biotech Holding ASA (the “Company”) held on 6 January 2015 resolved to conduct a rights issue of 7 million shares in the Company at a subscription price of NOK 10.00 per offer share. Shareholders in the Company, as evidenced in the Company's shareholders register in the Norwegian Central Securities Depository as at 8 January 2015, are granted tradable subscription rights which, subject to applicable securities laws, provide a right to subscribe for, and be allocated, one offer share in the rights issue. Each shareholder will be granted 0.906 subscription rights for each share in the Company registered as held by such shareholder as at 8 January 2015 (rounded down to the nearest whole subscription right). Over-subscription and subscription without subscription rights is allowed.

The subscription period for the rights issue commences on 20 January 2015 and will expire on 3 February 2015 at 16:30 hours (CET).

The subscription rights will be listed on Oslo Axess under the ticker “PCIB T” and will be tradable from 20 January 2015 to 3 February 2015 at 16:30 (CET).

The subscription rights are expected to have commercial value. The subscription rights that are not used to subscribe for new shares or not sold before 3 February 2015 at 16:30 CET, will lapse without compensation to the holder and consequently be of no value.

The Rights Issue is further described in the prospectus dated 19 January 2015. The prospectus as well as an online subscription solution* can be accessed here: www.dnb.no/emisjoner and

www.fondsfinans.no/no/tag/ongoing/

 *Online subscription solution available only for residents of Norway with a Norwegian personal identification number.